The best target group for surveillance after curative surgery is the stage III and postcurative stage IV disease group of patients. Most patients who relapse will do so 3 to 5 years after surgery. Newer drugs might delay the relapse period. Overall, only a small number of patients will benefit. There is a need for large, well designed, randomized studies, but these are difficult to do. Additional techniques will have to be validated as they come along. A general recommendation at the present time could be: physician evaluation, carcinoembryonic antigen testing, liver imaging, and colonoscopy. The frequency of these modalities at 3 and 6 months seems reasonable knowing that there is no final survival advantage demonstrated by randomized studies as of yet.